Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

NTase Products and Cyclic Nucleotide Signalling

Project description

Identifying novel cyclic nucleotide signalling in humans

Cell survival depends on processing environmental information, primarily through second messengers like cyclic nucleotides (CNs). CNs are diverse and significant in bacteria and humans, and show promise in cancer immunotherapy. However, many human nucleotidyltransferases (NTases) remain uncharacterised in the absence of their ligands. The ERC-funded NTasePro project will uncover the molecular functions of uncharacterised NTases and identify novel CN signalling pathways in humans, focusing on both immune and non-immune contexts. It will activate these NTases and explore their roles in immune responses. This approach suggests that uncharacterised CNs are critical for immune signalling and other pathways. Results could reveal new biological regulation mechanisms and pave the way for new therapeutic options using CNs as drugs.

Objective

Survival of a cell depends on its ability to receive and process information coming from the environment. Second messengers are the key transmitters of information that rapidly amplify the signal inside the cell. Cyclic nucleotides (CNs) are the most diversified category of second messengers and are found in all organisms modulating diverse pathways. CNs are best studied in bacteria, where they have a variety of biological functions. In humans, the only described cyclic di-nucleotide is cGAMP, which elicits an antiviral immune response. cGAMP is rapidly emerging as a promising drug candidate in e.g. cancer immunotherapy. I hypothesise that additional CNs contribute to yet uncharacterized pathways in humans and my aim is to discover novel CNs and their signalling pathways. CNs are synthesized by nucleotidyltransferases (NTases) and many human NTases remain uncharacterized by the lack of activity in the absence of the cognate ligand.

This project aims to reveal the molecular function of uncharacterized NTases and to discover novel CN signalling pathways in humans in immune and non-immune-related areas of biology. I will focus in Objective on the activation of as yet uncharacterized NTases and in Objective I want to identify CN signalling pathways involved in immune responses and beyond. The proposed experiments will provide me with candidates and precedence for CN signalling in humans other than cGAMP. The concept that yet uncharacterized CNs are involved in immune signalling as well as other pathways is highly innovative. Together, the well-studied activities in bacteria and the overall conservation of NTases in humans, further support fundamental involvement of CN signalling in humans. My proposed research will open up conceptually new modes of regulation in human biology, reveal novel signalling pathways and in the long-term contribute to new therapeutic options using CNs as drugs.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-STG

See all projects funded under this call

Host institution

TECHNISCHE UNIVERSITAET MUENCHEN
Net EU contribution
€ 1 755 873,00
Address
Arcisstrasse 21
80333 Muenchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 755 873,00

Beneficiaries (1)